Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Yes, that information does make a great case for kevetrin. I'll be happy to see the end results of the kevetrin ph2a OC trial. Being a tough one to enroll, this one may fall behind schedule.

Thankfully, the brilacidin ph2 OM trial appears to suddenly be ahead of schedule. The great interim results must have made it easier to enroll patients.

Speaking on interim results, I'd sure like to see prurisol top line data at the end rather than interim results. But, it's not my call. I'd just like to see Brilacidin OM results first.






In Reply to 'CallMeCrazy'
A very interesting video. In my mind, Barbara A. Burtness, MD (Yale Univ Sch of Med), made a good case as to why Kevetrin, if proven to restore function to mutated p53, will become a highly-prized, very valuable, combo-therapy drug in the area of Head and Neck Cancers.

Barbara A. Burtness, MD:

"Cancer Genome Atlas now has more than 500 head and neck cancers in it."

"One of the challenges for head and neck cancer has been that many of the mutations that we find are in tumor-suppressor genes. And there is often not—or to date, there has not been—a medication that can directly restore the function, say, of mutated p53....our increasing understanding of the complexity of the mutational profile, both in HPV-positive and HPV-negative disease, has not led to immediately using targeted therapy in head and neck cancer the way it has in some other solid tumors,"

"There is an observation that if a p53 mutation is disruptive for patients who’ve had good surgery, with negative margins, and then got appropriate risk-based adjuvant therapy, the patients with that disruptive p53 mutation are more likely to die. There’s a lot of preclinical evidence that says they are more radio-resistant, and there is some suggestion that you can overcome that with platinum."

http://www.onclive.com/peer-exchange/looking-forward-hnscc/genetic-landscape-of-hnscc